HUE028129T2 - Új készítmények lizoszómális tárolási rendellenességek megelõzésére és/vagy kezelésére - Google Patents

Új készítmények lizoszómális tárolási rendellenességek megelõzésére és/vagy kezelésére Download PDF

Info

Publication number
HUE028129T2
HUE028129T2 HUE10825397A HUE10825397A HUE028129T2 HU E028129 T2 HUE028129 T2 HU E028129T2 HU E10825397 A HUE10825397 A HU E10825397A HU E10825397 A HUE10825397 A HU E10825397A HU E028129 T2 HUE028129 T2 HU E028129T2
Authority
HU
Hungary
Prior art keywords
yky
diol
hydrogen
compound
piperidine
Prior art date
Application number
HUE10825397A
Other languages
English (en)
Inventor
Robert Boyd
Gary Lee
Philip Rybczynski
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of HUE028129T2 publication Critical patent/HUE028129T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/15Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (1)

  1. iy KÊSZfïliÉWEK UZOSZÓMÁUS TAROLÁS? RENDELLENESSÉGEK «ÔELÔEÉSÉRE émtMM KEZELÉSÉRE Szabadalmi igéay|mntok 1. íií) képleté vegyül«:
    ahol; R:|e&amp;Ä:€pä)(R:')(R^: !€ jelésgéss: hidrogén, -Œ vagy kalögép; &amp;.3 iskahlss hidrogén,: halogén vagy -CH3; R* jhilbiése halogén, -0¾ fend, iODéoiéad, nsekiiénii cikiöhlgilänetil, ahol ha R* jelentése halogén. Rs és R:: egÿsnért'e oerakdret hidrogén; R*' Is R* 8: Szénakmnnal egÿirtg «raeiyhss: kapcsolódnak, akloalkil 1¾¾¾¾ alkothatsz ankíy adott esetben snobszidoáim fchééégy Vagy iihl hhlogloltomíisal:;: R* jelealéss: Lidivgés vagy Itólsikit;: Z adok esetbeavan jeles, és bájaién varr, Zleiéstése -{CK^K --0(-01-. »S(k-U).:NH-, ~S{-ö)}·-, *S(“0)r -Ciír> C(“0)"RM-s -Sí«=0}rMR% -€(->>};ΝΜ~ w*C|“OP;*; Rjefcmlss («drogén vagy 0¾ S? jekaElse hidrogén vagy &amp;tni»id«ntÄik: R? jelentése -ÖH vagy halogén;; és R8 jelentése hidrogfe hatogén vagy hC%». Sïxai a íeUstsSeL hogy mernem Ki1 jelentése halogén 10 és 10 egyszerre tkan fejhet hidrogén, Is M Z sincs jeien, R ’ jeteräese -ŐR, R5, R^és R8 jeiestése fthteges; vagy gvógyá-szstilag eítpgadhaíó sója vagy szolváija; UhószómMis tárolási reotólenesslg ïSëpMlîdséhen ésivagy kezelésében itjrÄö afealesazhsta ilyen betegséggel disgsoszbzlítvngy klalalodásásak veszélyét hotáozó pásóenshen. %.M 1. igénypont szerinti vegyitlét as ott s^glndátpeott: nlkalmogásra, ahoi a vegyübl (ül) képistü vegyidéi:
    ahoi R( jtàmése CíR'XR'XK.*); R~ joisotése Idotogest, -ÖM vagy balogét!;, R^jeleróse Mbrogéît, -OS, balogba vagy -0¾ ; Ri! jekstëse balogét!, -CH3, feaii fteoadhctü, m«$t8emly cíklotoiísetíll,. ahol ha R* jelentése halogéa, R-< és RJ egyszerre. a«}» Msei hidrogóa; RJ és R* a .saéaaíoaaaaí «gyM, aajeiyhes kapcsolódjak:, cMosMí gyűrűt alkothatnak, amely adott esetboa stmhsdkaáSsai lehet egy vagy több hstogé®atotamal; R? jdeatése,~Oí$; R* jdéstése hidrogén;; és Rs jelentése hidrogés, aszd a feltétellel, hogy ha R* jelentése halogén R'{ és R's egyszerre nein lehet hláregére 3, Vegyüleí, arseiy az alábbiak közű; vâlssîsloK:
    vsgÿ :gy6gyteÄg «Èfeg«iti»tô sója vagy- dtí#> 'W «^: * ym km&amp;Wdöp;. iassshmáisi· tárolási :®smd#i?e«e&amp;#g; mm»2ésábm ésmm kmumm m鮧 alkstaaÄs Üyea beisgségg«! <!kgíu>^íís^i v;^y kMsfesáástesk veszélyét k»áoxé pfese®sbfö3i. 4, A3, ïgénypmi sæsriati vagyaiét az m meghaí&amp;ömít a&amp;ahaazásía, shoî a aegyäle!::
    vagy gyógyá^aíilagd&amp;gadhaíö segít vagy sscolvstja. $. A3L igéaypoaístó^ a&amp;atate, «tot* vqpOat:
    vagy gyágyáxzaülag dibgadhsíö adja -yagyszölváti». 4 A% ig éoypömmmrn vegyhletaaöd œ^#p4ÂWÉI #al&amp; vggyüfe
    yagy gyógyászati tag díbgadható soja vagy «sölvaíjs. ?, Λ 3. gykypom szvrinb vagyaiéi aaöií meghai&amp;swsoit alkalmazásra, ahol a yegyőfee
    vagy gydgyásKaliiag eiiagadhatb sôjg^a&amp;yÂtv:à§a, §, A 3. igésypimt sarnad vegyülik aas'élít îj*é^iaife^ôîï.-àïfcfe8âài^ray ahoi! a Vvgpsiet;
    vagy gyôgyitsxâiîlag elfogadható sója vagy azok álja. %m ëm iggtypowtifc bm&amp;ptæ asöirjtwi aS 0ίΐ ταφ&amp;κα&amp; tifektauâsô, É*óí £ ÂSæàS ikolM teäijp# j&amp;ite t-1 Igénypontok hfonsly&amp;e mxwâ v<eg3Ât «k oït m^mérmot éàaÉ« afe&amp;l a ifeosaoiatlis íároifeí restlsllssesség Kkueker^setsgség. Π, Az 1-Mî. igèoygositôk Mtoislyîke eaentvtl vegydtitt =acss ott soeghsigsoaoii akstea;ksxa, tegstäsb egy másik tooipiâs sseets! kombmáeiób&amp;ö, JJ, a il. igénypont szerinti vegyniet m oit meghasároxott »Ikahrn&amp;zássra, aho! a legalább egy másik terápiás éger knigtooeràx vagy I toobatllimkio.)' I ..i-tSîtlexxïai -D-gîaclioî B. Kásáiét, stpoly iaialmax:: » egy îattâlyt a következő Mplotü vegplekftstásos thenopségéy#:
    vagy gyégyssxáhiág el fogadható sofa vagy sxohoiífa; és » gonek hasiggáiad utasítását íigösKökális támlást readellonesség megelőzésére vagy késelésére.
HUE10825397A 2009-10-19 2010-10-05 Új készítmények lizoszómális tárolási rendellenességek megelõzésére és/vagy kezelésére HUE028129T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25280609P 2009-10-19 2009-10-19

Publications (1)

Publication Number Publication Date
HUE028129T2 true HUE028129T2 (hu) 2016-11-28

Family

ID=43879464

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE10825397A HUE028129T2 (hu) 2009-10-19 2010-10-05 Új készítmények lizoszómális tárolási rendellenességek megelõzésére és/vagy kezelésére
HUE15183960A HUE041971T2 (hu) 2009-10-19 2010-10-05 Új készítmények lizoszomális tárolási rendellenességek kezelésére és/vagy megelõzésére

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15183960A HUE041971T2 (hu) 2009-10-19 2010-10-05 Új készítmények lizoszomális tárolási rendellenességek kezelésére és/vagy megelõzésére

Country Status (26)

Country Link
US (3) US8604057B2 (hu)
EP (2) EP2490533B1 (hu)
JP (3) JP6147005B2 (hu)
KR (1) KR101848938B1 (hu)
CN (2) CN105193802A (hu)
AR (1) AR078607A1 (hu)
AU (2) AU2010308397B2 (hu)
BR (1) BR112012009123A2 (hu)
CA (1) CA2778349C (hu)
DK (2) DK2490533T3 (hu)
ES (2) ES2555533T3 (hu)
HK (2) HK1218082A1 (hu)
HR (2) HRP20151279T1 (hu)
HU (2) HUE028129T2 (hu)
IL (1) IL219231A0 (hu)
LT (1) LT2995306T (hu)
MX (1) MX337933B (hu)
PL (2) PL2490533T3 (hu)
PT (2) PT2490533E (hu)
RS (2) RS58466B1 (hu)
RU (2) RU2608520C2 (hu)
SI (2) SI2995306T1 (hu)
SM (1) SMT201500280B (hu)
TR (1) TR201903901T4 (hu)
TW (2) TWI587859B (hu)
WO (1) WO2011049737A1 (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056596A1 (en) * 2000-02-04 2001-08-09 Children's Hospital Research Foundation Use of lysosomal acid lipase for treating atherosclerosis and related diseases
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
WO2007030375A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
DK2490532T3 (en) * 2009-10-19 2017-02-27 Amicus Therapeutics Inc Hitherto UNKNOWN COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF DEGENERATIVE DISORDERS IN THE CENTRAL Nervous System
ES2555533T3 (es) * 2009-10-19 2016-01-04 Amicus Therapeutics, Inc. Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal
CN105214076B (zh) 2010-04-23 2020-03-31 辛那杰瓦生物制药股份有限公司 溶酶体贮积病酶
MX2013002704A (es) 2010-09-09 2013-09-13 Synageva Biopharma Corp Uso de acido lipasa lisosomal para tratar la deficiencia de acido lipasa lisosomal en pacientes.
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
EP2721151B1 (en) * 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
EP3741384A1 (en) 2011-09-07 2020-11-25 Mount Sinai School Of Medicine Ceramidase and cell differentiation
MX354127B (es) 2012-03-27 2018-02-14 Amicus Therapeutics Inc Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.
WO2013181530A1 (en) 2012-06-01 2013-12-05 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
PL2968479T3 (pl) 2013-03-14 2019-10-31 Icahn School Med Mount Sinai Kompozycje terapeutyczne ceramidazy kwasowej i sposoby ich wytwarzania i stosowania
WO2015095963A1 (en) 2013-12-23 2015-07-02 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
JP2017505350A (ja) * 2014-02-12 2017-02-16 アミカス セラピューティックス インコーポレイテッド 硫黄含有部分を含む糖誘導体ならびにその作製方法およびmps iiicの処置のためのその使用方法
KR20170083146A (ko) * 2014-11-19 2017-07-17 러쉬 유니버시티 메디컬 센터 리소좀 질환들의 치료를 위한 방법들 및 조성물들
EP3088389A1 (en) * 2015-04-28 2016-11-02 Dorphan S.A. 4-epi-isofagomine derivatives
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
EP3562821B9 (en) 2016-12-28 2021-05-26 Minoryx Therapeutics S.L. Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
AU2017388466B2 (en) 2016-12-29 2022-04-28 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
CN108524952A (zh) * 2017-03-06 2018-09-14 复旦大学 腺相关病毒aav9及其在制备治疗戈谢氏病的制剂中的用途
CA3061354A1 (en) 2017-04-25 2018-11-01 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
US20220016105A1 (en) * 2018-11-13 2022-01-20 EDWARD Via COLLEGE OF OSTEOPATHIC MEDICINE Biased nmda receptor modulators and uses thereof
BR112022010127A2 (pt) 2019-11-25 2022-09-06 Gain Therapeutics Sa Compostos de arila e heteroarila e usos terapêuticos dos mesmos em condições associadas à alteração da atividade de galatocerebrosidase
WO2021105908A1 (en) 2019-11-25 2021-06-03 Gain Therapeutics Sa Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase
CA3164707A1 (en) 2020-02-03 2021-08-12 Ana Maria Garcia Collazo Combination therapy for treating mps1
WO2022212268A1 (en) * 2021-03-29 2022-10-06 Sanford Health Methods and compositions for treating lysosomal storage disorders
WO2023042177A1 (en) 2021-09-20 2023-03-23 Gt Gain Therapeutics Sa Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide
WO2024141998A1 (en) 2022-12-30 2024-07-04 Gt Gain Therapeutics Sa Method of treating tauopathies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
DE69221484T2 (de) 1991-04-25 1998-02-19 Univ Brown Res Found Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2003273762A1 (en) 2002-10-28 2004-05-13 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US20040082641A1 (en) * 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
CA2548313A1 (en) * 2003-12-23 2005-07-14 Musc Foundation For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
ES2364586T3 (es) * 2006-05-24 2011-09-07 Amicus Therapeutics, Inc. Sal tartrato de isofagomina y métodos de uso.
DK1860101T3 (da) * 2006-05-24 2011-07-25 Amicus Therapeutics Inc Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf
DK2040548T3 (da) 2006-06-23 2012-08-13 Amicus Therapeutics Inc Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase
EP2150254A4 (en) 2007-04-26 2010-11-10 Amicus Therapeutics Inc DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
CN102625661B (zh) * 2009-04-09 2015-05-27 阿米库斯治疗学公司 用于预防和/或治疗溶酶体贮积失调的方法
NZ595630A (en) 2009-04-09 2013-04-26 Amicus Therapeutics Inc Methods for preventing and/or treating degenerative disorders of the central nervous system
ES2555533T3 (es) * 2009-10-19 2016-01-04 Amicus Therapeutics, Inc. Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal
DK2490532T3 (en) 2009-10-19 2017-02-27 Amicus Therapeutics Inc Hitherto UNKNOWN COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF DEGENERATIVE DISORDERS IN THE CENTRAL Nervous System
MX354127B (es) * 2012-03-27 2018-02-14 Amicus Therapeutics Inc Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.
KR102023720B1 (ko) 2012-09-03 2019-09-20 엘지이노텍 주식회사 보이스 코일 모터
US10179128B2 (en) * 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system

Also Published As

Publication number Publication date
WO2011049737A1 (en) 2011-04-28
DK2995306T3 (en) 2019-04-08
TW201117811A (en) 2011-06-01
SI2490533T1 (sl) 2016-01-29
SI2995306T1 (sl) 2019-04-30
KR20120099437A (ko) 2012-09-10
TR201903901T4 (tr) 2019-04-22
CN105193802A (zh) 2015-12-30
CN102647905B (zh) 2015-09-09
JP2013508367A (ja) 2013-03-07
RU2016103139A (ru) 2018-11-22
EP2995306A1 (en) 2016-03-16
JP2018035164A (ja) 2018-03-08
US20110091442A1 (en) 2011-04-21
TWI587859B (zh) 2017-06-21
RU2608520C2 (ru) 2017-01-19
EP2995306B1 (en) 2018-12-19
MX337933B (es) 2016-03-29
AU2016203840A1 (en) 2016-06-23
ES2716871T3 (es) 2019-06-17
IL219231A0 (en) 2012-06-28
MX2012004551A (es) 2012-07-04
DK2490533T3 (en) 2015-12-07
JP2016145194A (ja) 2016-08-12
RS58466B1 (sr) 2019-04-30
TW201603811A (zh) 2016-02-01
EP2490533A4 (en) 2013-05-29
HUE041971T2 (hu) 2019-06-28
US10035766B2 (en) 2018-07-31
CA2778349C (en) 2018-12-04
US8604057B2 (en) 2013-12-10
AU2010308397A1 (en) 2012-05-10
HK1174201A1 (zh) 2013-06-07
TWI558396B (zh) 2016-11-21
CN102647905A (zh) 2012-08-22
CA2778349A1 (en) 2011-04-28
EP2490533A1 (en) 2012-08-29
ES2555533T3 (es) 2016-01-04
JP6147005B2 (ja) 2017-06-14
KR101848938B1 (ko) 2018-04-13
RU2012120760A (ru) 2013-11-27
PT2490533E (pt) 2016-01-13
SMT201500280B (it) 2016-01-08
US20180334432A1 (en) 2018-11-22
PT2995306T (pt) 2019-03-29
HRP20190521T1 (hr) 2019-05-17
EP2490533B1 (en) 2015-09-16
US20140086896A1 (en) 2014-03-27
HK1218082A1 (zh) 2017-02-03
PL2490533T3 (pl) 2016-02-29
AU2010308397B2 (en) 2016-04-07
BR112012009123A2 (pt) 2017-09-19
PL2995306T3 (pl) 2019-07-31
LT2995306T (lt) 2019-04-10
PL2995306T4 (pl) 2019-07-31
HRP20151279T1 (hr) 2016-01-01
AR078607A1 (es) 2011-11-23
RS54466B1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
DK2490533T3 (en) NOVEL COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF Lysosomal Storage DISEASES
JP5645918B2 (ja) リソソーム蓄積障害の予防および/または治療方法
AU2017272296B2 (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
US8304429B2 (en) Methods for preventing and/or treating degenerative disorders of the central nervous system